Matches in Wikidata for { <http://www.wikidata.org/entity/Q92616278> ?p ?o ?g. }
Showing items 1 to 51 of
51
with 100 items per page.
- Q92616278 description "article scientifique publié en 2018" @default.
- Q92616278 description "artículu científicu espublizáu en payares de 2018" @default.
- Q92616278 description "im November 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q92616278 description "scientific article published on 20 November 2018" @default.
- Q92616278 description "wetenschappelijk artikel" @default.
- Q92616278 description "наукова стаття, опублікована в листопаді 2018" @default.
- Q92616278 name "Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden" @default.
- Q92616278 name "Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden" @default.
- Q92616278 type Item @default.
- Q92616278 label "Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden" @default.
- Q92616278 label "Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden" @default.
- Q92616278 prefLabel "Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden" @default.
- Q92616278 prefLabel "Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden" @default.
- Q92616278 P1433 Q92616278-EC25BC49-3CA0-4A10-B4AD-AE93CE10642C @default.
- Q92616278 P1476 Q92616278-FB643E65-134E-4CCC-909C-D6F09FF694D0 @default.
- Q92616278 P2093 Q92616278-2DAED2D2-407A-4E91-B2F4-50494B260165 @default.
- Q92616278 P2093 Q92616278-395351DA-75B2-4079-B0F7-B46032F7BF50 @default.
- Q92616278 P2093 Q92616278-39D18C41-6F02-4CC9-B8F1-9CE7174F0210 @default.
- Q92616278 P2093 Q92616278-5399A239-1EC0-4E4B-96ED-62480EE31EF9 @default.
- Q92616278 P2093 Q92616278-9D591DB1-113A-43A1-94A7-AC8748B7B4A6 @default.
- Q92616278 P2093 Q92616278-B4AA4232-B313-4669-B6D8-ACBDC3C00A52 @default.
- Q92616278 P2093 Q92616278-B876E649-70C0-4A8E-8D16-E19D5D354CBA @default.
- Q92616278 P2093 Q92616278-C1AC2E0D-DA2F-4792-9F64-32073E1B3CCB @default.
- Q92616278 P2093 Q92616278-F55F7A79-DE91-4681-945A-ACBEFA63B695 @default.
- Q92616278 P2093 Q92616278-FB62CD89-2689-4B68-B737-3E2EFC3B672B @default.
- Q92616278 P31 Q92616278-ADF47EE8-EF1B-46FE-8401-249C05D07487 @default.
- Q92616278 P356 Q92616278-CD68A769-64D6-4BB7-ABE1-9B82DA14AC8C @default.
- Q92616278 P577 Q92616278-2490E63D-B5E1-4B4F-B2F4-53E490ADA139 @default.
- Q92616278 P698 Q92616278-0D8A6C80-6238-4899-B172-13B8B4A8B634 @default.
- Q92616278 P921 Q92616278-3D84FC51-ECB8-4200-9FF3-5DAF0B78DB1C @default.
- Q92616278 P921 Q92616278-D44DE11D-7281-4109-A8D6-4CD1B5987234 @default.
- Q92616278 P356 J.EUO.2018.09.012 @default.
- Q92616278 P698 31412001 @default.
- Q92616278 P1433 Q63882907 @default.
- Q92616278 P1476 "Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden" @default.
- Q92616278 P2093 "Haojie Li" @default.
- Q92616278 P2093 "James M Pellissier" @default.
- Q92616278 P2093 "Natalie Zarabi" @default.
- Q92616278 P2093 "Rodolfo F Perini" @default.
- Q92616278 P2093 "Ronac Mamtani" @default.
- Q92616278 P2093 "Ronald de Wit" @default.
- Q92616278 P2093 "Ruifeng Xu" @default.
- Q92616278 P2093 "Tushar Srivastava" @default.
- Q92616278 P2093 "Vimalanand S Prabhu" @default.
- Q92616278 P2093 "Yichen Zhong" @default.
- Q92616278 P31 Q13442814 @default.
- Q92616278 P356 "10.1016/J.EUO.2018.09.012" @default.
- Q92616278 P577 "2018-11-20T00:00:00Z" @default.
- Q92616278 P698 "31412001" @default.
- Q92616278 P921 Q13896859 @default.
- Q92616278 P921 Q34 @default.